BD1 Ann Today:
• Option Agreement signed with the University of Liverpool to license two novel protein markers for development and commercialisation of a novel type 3c diabetes (T3cDM) blood test
• T3cDM accounts for up to 10% of new-onset diabetes cases, but it is currently underdiagnosed and poorly managed
• BARD1 is also developing blood tests for early detection of pancreatic cancer and an accurate T3cDM test could enable better management of T3cDM and stratification of people at risk of developing pancreatic cancer
- Forums
- ASX - Day Trading
- Afternoon trading April 13
Afternoon trading April 13, page-2
-
- There are more pages in this discussion • 234 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online